120 research outputs found
A Representative User-centric Dataset of 10 Million GitHub Developers
No full textUsing GitHub APIs, we construct an unbiased dataset of over 10 million GitHub users. The data was collected between Jul. 20 and Aug. 27, 2018, covering 10,649,574 users, 118,602,740 commits, and 20,999,258 repositories. Each data entry is stored in JSON format, representing one GitHub user, and containing the descriptive information in the user’s profile page, the information of her commit activities and created/forked public repositories
A Representative User-centric Dataset of 10 Million GitHub Developers
No full textUsing GitHub APIs, we construct an unbiased dataset of over 10 million GitHub users. The data was collected between Jul. 20 and Aug. 27, 2018, covering 10,649,574 users, 118,602,740 commits, and 20,999,258 repositories. Each data entry is stored in JSON format, representing one GitHub user, and containing the descriptive information in the user’s profile page, the information of her commit activities and created/forked public repositories
Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
No full textJiayun Jiang,1 Hui Zhang,1 Jiejuan Lai,1 Shiyu Zhang,1 Yanjiao Ou,1 Yu Fu,2,* Leida Zhang1,* 1Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China; 2Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Leida Zhang, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), No. 30, Gaotanyan Street, Shapingba District, Chongqing, 400038, People’s Republic of China, Email [email protected] Yu Fu, Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, No. 2, Tiansheng Road, Beibei District, Chongqing, 400715, People’s Republic of China, Email [email protected]: To compare the efficacy and safety of transarterial chemoembolization (TACE) plus lenvatinib and tislelizumab (TACE-Len-T) versus TACE plus lenvatinib (TACE-Len) as the first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).Patients and Methods: This retrospective study included 136 uHCC patients treated with TACE-Len-T or TACE-Len from January 1, 2021, to June 30, 2023. Clinical outcomes including overall survival (OS), progression-free survival (PFS), tumor response and adverse events (AEs) were compared between the two groups. The risk factors affecting OS and PFS were also analyzed.Results: The median OS and PFS of the TACE-Len-T group were significantly longer than those of the TACE-Len group (Median OS: not reached vs 13.8 months, P 3, and cTACE were independent risk factors for OS, whereas TACE-Len treatment was the only independent risk factor for PFS. The frequency and severity of AEs in the TACE-Len-T group were comparable to those in the TACE-Len group (any grade: 92.6% vs 91.2%, P=0.753; grade 3 or 4: 33.8% vs 32.3%, P=0.855).Conclusion: TACE-Len-T treatment significantly improved OS, PFS, ORR, and DCR over TACE-Len treatment, with a manageable safety profile in uHCC.Keywords: unresectable hepatocellular carcinoma, transarterial chemoembolization, lenvatinib, tislelizumab, immunotherap
The Space of Dynamic Informality
No full textToday's standard spatial experience of the contemporary city is like one of a continuous sequence of small homogeneous functional enclaves via thresholds and leftover spaces, which can be summarized as the 'margins', where plenty of temporary or long-lasting informal practices take place. Those marginal spaces, as well as informal practices they host, are being mostly ignored, but still, have great potentials. They are under constant change, always reflecting the needs of their occupants and inhabitants. Interested in this hidden layer of urban ecology, my concern is how can we as an architect react to the existing informal practices, not in way of negation and demolishment, but respect and continuation. My proposal does not pretend to be able to govern the current processes within the site I studied, nor does it pretend to offer solutions to straightforward problems, for example, ‘problems’ within those informal communities along Baku's railway I investigated - actually it is controversial to decide if the ‘problems’ need to be solved or if there are really 'problems' exist. Instead, I applied the theories and image study methods from my research to the new practice. In a complex block with potential in Tbilisi, I introduce a set of infrastructure, which offers marginal spaces available for occupation and use. The characteristics I've concluded in research should also reflect in the materialization.Architecture, Urbanism and Building Science
FROM AVOIDANCE TO HEALING: THE PORTRAYAL OF DEATH IN CONTEMPORARY CHILDREN\u27S LITERATURE
No full textThis thesis examines the portrayal of death in children\u27s literature from three different perspectives. Firstly, it explores how authors approached the topic during the Victorian era when death was an everyday reality due to rampant diseases. Secondly, it analyzes how authors depict death in different ways, including involuntary death, the pursuit of the sublime, and the nature of life cycle. Thirdly, it explores how authors address children\u27s psychological states when dealing with death, including reducing pre-death pain, using poetic expression, promoting healing from grief, and associating memory loss with death. Finally, the author creates a children\u27s book that confronts the author\u27s own fear of death and the loss of loved ones.In conclusion, this thesis highlights the evolution of the portrayal of death in children\u27s literature, from avoiding the topic altogether to acknowledging it as an inevitable reality. The contemporary approach focuses on alleviating children\u27s fear of death and guiding them through the grieving process with healing words and images, emphasizing love, resilience, and memory
Recommended from our members
A Goal-Striving Model for Consumers' Deliberate Counterfeit-Consumption Behavior
No full textCounterfeit consumption is becoming widespread, developing into a problem of international significance. In an attempt to develop a refined understanding of the motivations and decision-making processes of consumers' deliberate counterfeit-consumption behavior, this empirical study not only integrates the theory of planned behavior and insights from self-regulatory theories, but also extends these theories by re-conceptualizing the relationships among key constructs with the inclusion of action desire. This research also introduces and integrates a new construct, namely consumers' Perceived Counterfeit Detection (PCD) by important others.Using a combination of qualitative and quantitative methods consisting of in-depth interviews and a self-administered paper questionnaire, this research empirically tested a proposed goal-striving model for deliberate counterfeit-consumption behavior, using structural equations modeling. Results demonstrated PCD's existence and supported a refined goal-striving model, based upon which effective strategies to decrease consumer's counterfeit consumption are discussed.Release January 1st, 2021Originally embargoed through 01-Jul-2016; extended embargo through 01-Jan-2018 per author request on 14-Jun-2016. Kimberl
HYDRATION AND DISSOCIATION OF CALCIUM HYDROXIDE IN WATER CLUSTERS: A QUANTUM CHEMICAL STUDY
No full textRegistration System Reform and Enterprise Innovation: Evidence from a Quasi-Natural Experiment of the Registration-Based IPO System Reform Pilot in China
No full textIn recent years, the registration-based IPO system has been gradually introduced and promoted in China’s capital market, and its implementation effect has attracted considerable attention. This paper focuses on companies that were first listed between 2019 and 2021. We empirically investigate the impact of the registration system reform on enterprise innovation using the staggered difference-in-differences model, with R&D investment as the measure of enterprise innovation. The findings demonstrate that, in comparison to companies listed via the approval system, those listed via the registration system exhibit a higher level of R&D investment in the three years following listing. This suggests that the reform of the registration system effectively stimulates an increase in R&D investment among IPO companies. Furthermore, the reform of the registration system has been found to significantly promote the R&D investment of IPO companies on the STAR Market (i.e., the Science and Technology Innovation Board), while having no significant impact on the R&D investment of IPO companies on the ChiNext Market (i.e., the Growth Enterprise Board). Further analysis indicates that the registration system reform encourages IPO firms to increase R&D investment by reducing agency costs, alleviating financing constraints, and accumulating human capital. This study elucidates the impact of registration system reform on enterprise innovation and its mechanism and provides novel empirical evidence for the evaluation of the effect of registration system reform pilot
Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
No full textJiayun Zhong,1 Yu Liu,2 Qian Fu,1 Dan Huang,2 Wenjun Gong,2 Jian Zou2 1Department of Pharmaceutical, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republic of China; 2Department of Clinical Pharmacy, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republic of ChinaCorrespondence: Jian Zou, Department of clinical pharmacy, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republic of China, Tel +86 28 86239898, Email [email protected]: Regorafenib, a novel multikinase inhibitor, has been approved by the US Food and Drug Administration as a standard treatment choice for metastatic colorectal cancer (mCRC). Nonetheless, its substantial cost places a significant burden on social health resources and patients. However, the cost-effectiveness (CE) of regorafenib compared to other third-line therapies is still undetermined.Objective: This study aims to assess the CE of regorafenib compared to other third-line therapies for the treatment of mCRC.Methods: We conducted a comprehensive literature search in PubMed, Medline, Scopus, Embase, Cochrane Library, as well as nine other databases to identify relevant studies published up to October 2023, focusing on patients with mCRC and examining the cost-effectiveness of regorafenib. Following the screening and extraction of pertinent data, the study quality was assessed using the Quality of Health Economic Studies (QHES) checklist.Results: The literature search yielded 751 records, and after applying the inclusion criteria, 13 studies from 7 different countries were included. Of these, 7 studies evaluated the cost-effectiveness of regorafenib compared to trifluridine/tipiracil (TAS-102), 3 studies compared regorafenib with best supportive care (BSC), and 3 studies compared regorafenib with fruquintinib, serplulimab, and regorafenib dose optimization (ReDo).The quality of the included studies was high with an average QHES scores of 85.62. Regorafenib standard dose proves to be less cost-effective than alternative third-line therapies. Implementing a dose optimization strategy could potentially rectify this disparity and enhance the cost-effectiveness of regorafenib.Conclusion: The use of the standard dose of regorafenib is generally regarded as not cost-effective when compared to other third-line therapies for patients with mCRC. However, implementing a dose-escalation strategy may enhance regorafenib’s cost-effectiveness. Consequently, significant price reductions or optimizing the dose of regorafenib are required to achieve cost-effectiveness.Keywords: regorafenib, metastatic colorectal cancer, cost-effectiveness, incremental cost-effectiveness ratio
- …
